Research Article - Archives of General Internal Medicine (2023) Volume 7, Issue 6

A Systematic Review on NSAIDs and Tanezumab efficacy in Chronic Lower Back Pain

Chronic back pain is a condition that impacts people of all ages and lasts longer than 12 weeks. 7.41% of all Years Lost to Disability (YLD) are attributed to low back pain, which makes it the pathology responsible for the most YLD, surpassing other chronic conditions such as diabetes and depression. Despite the prevalence of drugs such as opioids, Non-Steroidal AntiInflammatory Drugs (NSAIDs), and biologics, the types of drugs administered to individuals differ greatly. We collected data from the PubMed database of the National Library of Medicine, PubMed Central, and Google Scholar. Randomized Controlled Trials (RCTs) that explicitly evaluate the efficacy of various NSAIDs in adult patients with chronic back pain were selected for this study. After an exhaustive search and examination of numerous publications, only 8 articles met the inclusion criteria. In recent studies that included NSAIDs, they were among the most frequently prescribed medications for the treatment of chronic low back pain. In comparison to placebo, selective COX-II inhibitors such as celecoxib and etoricoxib were found to be efficacious, while valdecoxib was associated with serious side effects. In addition to reducing back pain, COX-II inhibitors with a preference for COX-II, such as aceclofenac and diclofenac, were associated with gastrointestinal side effects. Despite the risk of joint degeneration and accelerated osteoarthritis, intravenous tanezumab may be superior to naproxen and placebo in treating chronic low back pain.

Author(s): Smaran Kasireddy , Sweta Sahu , Lyluma Ishfaq , Berjis Rahmath , Navya Pillikunte Doddareddy , Mudit Moondra6 , Mihirkumar P. Parmar ,Vishal Venugopal

Abstract Full Text PDF